Absci Corporation and AstraZeneca have teamed up to fast-track the development of a potential new cancer treatment, an AI-designed antibody, using Absci’s Integrated Drug Creation™ platform. Absci will provide the AI expertise while AstraZeneca offers its oncology expertise. The platform will use a feedback loop including data collection, AI-driven design, and wet-lab validation.
The problem with laboratory reference ranges
Tonight, my lab quietly changed what it considers a “normal” ApoB. On Monday, my patient’s ApoB of 98 mg/dL was comfortably green. On Tuesday, that
